William A Prescott1. 1. University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, and the Department of Pediatrics, University at Buffalo School of Medicine, Buffalo, New York.
Abstract
OBJECTIVES: The Cystic Fibrosis Foundation recently deemed the use of extended-interval dosing (EID) of aminoglycosides acceptable for the treatment of cystic fibrosis (CF) pulmonary exacerbations, but current practices across United States (US) pediatric CF accredited care centers and affiliate programs are unknown. The objectives of this research are to characterize the practice trends, dosing strategies, therapeutic drug monitoring practices, and adverse drug reaction monitoring of EID of aminoglycosides in the treatment of pulmonary exacerbations across US pediatric CF programs. METHODS: A 38-question online survey was distributed on behalf of the author by the CF Foundation to all US pediatric CF accredited care centers and affiliate programs. RESULTS: Of the 70 participating CF programs (42.2% survey response rate), 94.3% reported using EID of aminoglycosides (as once-daily or twice-daily dosing), whereas 84.3% reported using once-daily EID in their pediatric CF population. The frequency of EID use increased with patient age. Tobramycin dosed 10 mg/kg per day every 24 hours, infused over the course of 30 minutes, in combination with an antipseudomonal beta-lactam, was the most commonly cited regimen. Monitoring of aminoglycoside serum concentrations was reported by 98.5% of programs, with a tobramycin peak of 25 to 30 mg/L and trough of less than 1 mg/L targeted most frequently. Nephrotoxicity was commonly monitored through serum creatinine measurements, whereas ototoxicity was monitored by audiometry in approximately one-half of programs. CONCLUSIONS: This study indicates that the use of EID of aminoglycosides across US pediatric CF accredited care centers and affiliate programs is common, particularly among adolescents, with tobramycin being the preferred agent.
OBJECTIVES: The Cystic Fibrosis Foundation recently deemed the use of extended-interval dosing (EID) of aminoglycosides acceptable for the treatment of cystic fibrosis (CF) pulmonary exacerbations, but current practices across United States (US) pediatric CF accredited care centers and affiliate programs are unknown. The objectives of this research are to characterize the practice trends, dosing strategies, therapeutic drug monitoring practices, and adverse drug reaction monitoring of EID of aminoglycosides in the treatment of pulmonary exacerbations across US pediatric CF programs. METHODS: A 38-question online survey was distributed on behalf of the author by the CF Foundation to all US pediatric CF accredited care centers and affiliate programs. RESULTS: Of the 70 participating CF programs (42.2% survey response rate), 94.3% reported using EID of aminoglycosides (as once-daily or twice-daily dosing), whereas 84.3% reported using once-daily EID in their pediatric CF population. The frequency of EID use increased with patient age. Tobramycin dosed 10 mg/kg per day every 24 hours, infused over the course of 30 minutes, in combination with an antipseudomonal beta-lactam, was the most commonly cited regimen. Monitoring of aminoglycoside serum concentrations was reported by 98.5% of programs, with a tobramycin peak of 25 to 30 mg/L and trough of less than 1 mg/L targeted most frequently. Nephrotoxicity was commonly monitored through serum creatinine measurements, whereas ototoxicity was monitored by audiometry in approximately one-half of programs. CONCLUSIONS: This study indicates that the use of EID of aminoglycosides across US pediatric CF accredited care centers and affiliate programs is common, particularly among adolescents, with tobramycin being the preferred agent.
Authors: Alan Smyth; Kelvin H-V Tan; Pauline Hyman-Taylor; Michael Mulheran; Sarah Lewis; David Stableforth; Alan Prof Knox Journal: Lancet Date: 2005 Feb 12-18 Impact factor: 79.321
Authors: V Master; G W Roberts; K P Coulthard; P A Baghurst; A Martin; M E Roberts; C R Onishko; A J Martin; R J Linke; M Holmes; A Jarvinen; D Kennedy; K A Colebatch; D Hansman; D W Parsons Journal: Pediatr Pulmonol Date: 2001-05
Authors: Despina G Contopoulos-Ioannidis; Nikos D Giotis; Dimitra V Baliatsa; John P A Ioannidis Journal: Pediatrics Date: 2004-07 Impact factor: 7.124
Authors: S H Powell; W L Thompson; M A Luthe; R C Stern; D A Grossniklaus; D D Bloxham; D L Groden; M R Jacobs; A O DiScenna; H A Cash; J D Klinger Journal: J Infect Dis Date: 1983-05 Impact factor: 5.226
Authors: Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Christopher H Goss; Randall L Rosenblatt; Robert J Kuhn; Bruce C Marshall Journal: Am J Respir Crit Care Med Date: 2009-09-03 Impact factor: 21.405
Authors: Cornelia B Landersdorfer; Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Tae Hwan Kim; Phillip J Bergen; Soon-Ee Cheah; John D Boyce; Anton Y Peleg; Antonio Oliver; Beom Soo Shin; Roger L Nation; Jürgen B Bulitta Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter Journal: J Antimicrob Chemother Date: 2021-10-11 Impact factor: 5.790
Authors: Angela C Garinis; Gayla L Poling; Ronald C Rubenstein; Dawn Konrad-Martin; Timothy E Hullar; David M Baguley; Holly L Burrows; Jennifer A Chisholm; Amy Custer; Laura Dreisbach Hawe; Lisa L Hunter; Theodore K Marras; Candice E Ortiz; Lucretia Petersen; Peter S Steyger; Kevin Winthrop; Erika M Zettner; Khaya Clark; Michelle Hungerford; Jay J Vachhani; Carmen C Brewer Journal: Am J Audiol Date: 2021-09-22 Impact factor: 1.636
Authors: Brianna Hemmann; Elizabeth Woods; Tanya Makhlouf; Chris Gillette; Courtney Perry; Mary Subramanian; Holly Hanes Journal: J Pediatr Pharmacol Ther Date: 2022-09-26